These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32929154)

  • 1. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
    Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT; Bindal S; Najjar MK; Zhuang C; Khan M; Arrigo ABJ; Gonzalez AO; Zhang XR; Zhu JJ; Watabe K; Lo HW
    Cancer Lett; 2024 Aug; 597():217023. PubMed ID: 38852701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
    Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Chica-Parrado MR; Kim GM; Uemoto Y; Napolitano F; Lin CC; Ye D; Bikorimana E; Fang Y; Lee KM; Mendiratta S; Hanker AB; Arteaga CL
    Cancer Lett; 2024 Nov; 604():217219. PubMed ID: 39244005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
    Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
    Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
    Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
    Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.
    Dagklis A; Demeyer S; De Bie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; de Bock CE; Cools J
    Blood; 2016 Dec; 128(23):2642-2654. PubMed ID: 27694322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo design of dual-target JAK2, SMO inhibitors based on deep reinforcement learning, molecular docking and molecular dynamics simulations.
    He L; Liu J; Zhao HL; Zhang LC; Yu RL; Kang CM
    Biochem Biophys Res Commun; 2023 Jan; 638():23-27. PubMed ID: 36436338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
    Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
    Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
    Ochi N; Isozaki H; Takeyama M; Singer JW; Yamane H; Honda Y; Kiura K; Takigawa N
    Exp Cell Res; 2016 Jun; 344(2):194-200. PubMed ID: 27180268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.
    Sirkisoon SR; Carpenter RL; Rimkus T; Doheny D; Zhu D; Aguayo NR; Xing F; Chan M; Ruiz J; Metheny-Barlow LJ; Strowd R; Lin J; Regua AT; Arrigo A; Anguelov M; Pasche B; Debinski W; Watabe K; Lo HW
    Oncogene; 2020 Jan; 39(1):64-78. PubMed ID: 31462709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.